RT Journal Article
SR Electronic
T1 Dasatinib-induced Crohn’s-like colitis
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP jclinpath-2022-208340
DO 10.1136/jclinpath-2022-208340
A1 Grillo, Federica
A1 Carlin, Luca
A1 Remo, Andrea
A1 Fassan, Matteo
A1 Mescoli, Claudia
A1 Campora, Michela
A1 Caserta, Luigi
A1 Mazza, Fabrizio
A1 Mastracci, Luca
YR 2022
UL http://jcp.bmj.com/content/early/2022/06/14/jclinpath-2022-208340.abstract
AB Dasatinib is a second-generation multityrosine kinase inhibitor used in the first-line and second-line treatment of Philadelphia chromosome-positive leukaemia. The most frequent type of Dasatinib-induced intestinal injury is haemorrhagic colitis; other morphologic patterns include apoptotic colopathy, CD8+ T-cell-mediated colitis and non-specific colitis. Aim of this study is to describe a novel Crohn’s-like histopathologic pattern of Dasatinib-induced colitis. Four patients developed diarrhoea during Dasatinib treatment; colonoscopy was performed and biopsy sets were taken for histological analysis. All patients showed patchy, chronic active inflammation with cryptitis and microgranulomas (two patients). Ileal and rectal biopsies showed either no or mild, focal inflammation. An increase in lamina propria eosinophils was seen (two patients) and apoptoses were seen (three patients). Complete remission was observed after interruption of treatment. Dasatinib-induced colitis and Crohn’s disease may share histologic features including microgranulomas, which can potentially lead to misdiagnosis if no information on treatment is provided.